



ATC codes: [L02AE02](#)

Indication	Malignant neoplasms of prostate <span>ICD11 code: <a href="#">2D32.Z</a></span>
INN	Leuprorelin
Medicine type	Chemical agent
List type	Complementary
Formulations	Parenteral > General injections > IM: 7.5 mg in prefilled syringe ; 22.5 mg in prefilled syringe
EML status history	First added in 2015 ( <a href="#">TRS 994</a> ) Changed in 2021 ( <a href="#">TRS 1035</a> )
Sex	Male
Age	Adolescents and adults
Therapeutic alternatives	<a href="#">goserelin</a> (ATC codes: <a href="#">L02AE03</a> ) <a href="#">triptorelin</a> (ATC codes: <a href="#">L02AE04</a> )
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 


#### Tags

Cancer

#### Wikipedia

[Leuprorelin](#) 

#### DrugBank

[Leuprorelin \(Leuprolide\)](#) 

## Summary of evidence and Expert Committee recommendations

Following the review of square box listings on the EML and EMLc, the Expert Committee recommended goserelin and triptorelin be specified as therapeutic alternatives under the square box listing for leuprorelin on the EML.

[Expert Committee report](#) 

